Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale

Beth Rachlis, Rakhi Karwa, Celia Chema, Sonak Pastakia, Sten Olsson, Kara Wools-Kaloustian, Beatrice Jakait, Mercy Maina, Marcel Yotebieng, Nagalingeswaran Kumarasamy, Aimee Freeman, Nathalie de Rekeneire, Stephany N. Duda, Mary Ann Davies, Paula Braitstein

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Targeted spontaneous reporting (TSR) is a pharmacovigilance method that can enhance reporting of adverse drug reactions related to antiretroviral therapy (ART). Minimal data exist on the needs or capacity of facilities to conduct TSR. Objectives: Using data from the International epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium, the present study had two objectives: (1) to develop a list of facility characteristics that could constitute key assets in the conduct of TSR; (2) to use this list as a starting point to describe the existing capacity of IeDEA-participating facilities to conduct pharmacovigilance through TSR. Methods: We generated our facility characteristics list using an iterative approach, through a review of relevant World Health Organization (WHO) and Uppsala Monitoring Centre documents focused on pharmacovigilance activities related to HIV and ART and consultation with expert stakeholders. IeDEA facility data were drawn from a 2009/2010 IeDEA site assessment that included reported characteristics of adult and pediatric HIV care programs, including outreach, staffing, laboratory capacity, adverse event monitoring, and non-HIV care. Results: A total of 137 facilities were included: East Africa (43); Asia–Pacific (28); West Africa (21); Southern Africa (19); Central Africa (12); Caribbean, Central, and South America (7); and North America (7). Key facility characteristics were grouped as follows: outcome ascertainment and follow-up; laboratory monitoring; documentation—sources and management of data; and human resources. Facility characteristics ranged by facility and region. The majority of facilities reported that patients were assigned a unique identification number (n = 114; 83.2 %) and most sites recorded adverse drug reactions (n = 101; 73.7 %), while 82 facilities (59.9 %) reported having an electronic database on site. Conclusion: We found minimal information is available about facility characteristics that may contribute to pharmacovigilance activities. Our findings, therefore, are a first step that can potentially assist implementers and facility staff to identify opportunities and leverage their existing capacities to incorporate TSR into their routine clinical programs.

Original languageEnglish (US)
Pages (from-to)1-18
Number of pages18
JournalDrug Safety
DOIs
StateAccepted/In press - Jun 9 2016

Fingerprint

Pharmacovigilance
Databases
Acquired Immunodeficiency Syndrome
Drug-Related Side Effects and Adverse Reactions
HIV
Central Africa
Southern Africa
Central America
Eastern Africa
Western Africa
South America
North America
Referral and Consultation
Pediatrics
Monitoring
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Toxicology

Cite this

Targeted Spontaneous Reporting : Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. / Rachlis, Beth; Karwa, Rakhi; Chema, Celia; Pastakia, Sonak; Olsson, Sten; Wools-Kaloustian, Kara; Jakait, Beatrice; Maina, Mercy; Yotebieng, Marcel; Kumarasamy, Nagalingeswaran; Freeman, Aimee; de Rekeneire, Nathalie; Duda, Stephany N.; Davies, Mary Ann; Braitstein, Paula.

In: Drug Safety, 09.06.2016, p. 1-18.

Research output: Contribution to journalArticle

Rachlis, B, Karwa, R, Chema, C, Pastakia, S, Olsson, S, Wools-Kaloustian, K, Jakait, B, Maina, M, Yotebieng, M, Kumarasamy, N, Freeman, A, de Rekeneire, N, Duda, SN, Davies, MA & Braitstein, P 2016, 'Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale', Drug Safety, pp. 1-18. https://doi.org/10.1007/s40264-016-0434-9
Rachlis, Beth ; Karwa, Rakhi ; Chema, Celia ; Pastakia, Sonak ; Olsson, Sten ; Wools-Kaloustian, Kara ; Jakait, Beatrice ; Maina, Mercy ; Yotebieng, Marcel ; Kumarasamy, Nagalingeswaran ; Freeman, Aimee ; de Rekeneire, Nathalie ; Duda, Stephany N. ; Davies, Mary Ann ; Braitstein, Paula. / Targeted Spontaneous Reporting : Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. In: Drug Safety. 2016 ; pp. 1-18.
@article{ed4b6bae97cf435894c7947d5a8c91dd,
title = "Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale",
abstract = "Introduction: Targeted spontaneous reporting (TSR) is a pharmacovigilance method that can enhance reporting of adverse drug reactions related to antiretroviral therapy (ART). Minimal data exist on the needs or capacity of facilities to conduct TSR. Objectives: Using data from the International epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium, the present study had two objectives: (1) to develop a list of facility characteristics that could constitute key assets in the conduct of TSR; (2) to use this list as a starting point to describe the existing capacity of IeDEA-participating facilities to conduct pharmacovigilance through TSR. Methods: We generated our facility characteristics list using an iterative approach, through a review of relevant World Health Organization (WHO) and Uppsala Monitoring Centre documents focused on pharmacovigilance activities related to HIV and ART and consultation with expert stakeholders. IeDEA facility data were drawn from a 2009/2010 IeDEA site assessment that included reported characteristics of adult and pediatric HIV care programs, including outreach, staffing, laboratory capacity, adverse event monitoring, and non-HIV care. Results: A total of 137 facilities were included: East Africa (43); Asia–Pacific (28); West Africa (21); Southern Africa (19); Central Africa (12); Caribbean, Central, and South America (7); and North America (7). Key facility characteristics were grouped as follows: outcome ascertainment and follow-up; laboratory monitoring; documentation—sources and management of data; and human resources. Facility characteristics ranged by facility and region. The majority of facilities reported that patients were assigned a unique identification number (n = 114; 83.2 {\%}) and most sites recorded adverse drug reactions (n = 101; 73.7 {\%}), while 82 facilities (59.9 {\%}) reported having an electronic database on site. Conclusion: We found minimal information is available about facility characteristics that may contribute to pharmacovigilance activities. Our findings, therefore, are a first step that can potentially assist implementers and facility staff to identify opportunities and leverage their existing capacities to incorporate TSR into their routine clinical programs.",
author = "Beth Rachlis and Rakhi Karwa and Celia Chema and Sonak Pastakia and Sten Olsson and Kara Wools-Kaloustian and Beatrice Jakait and Mercy Maina and Marcel Yotebieng and Nagalingeswaran Kumarasamy and Aimee Freeman and {de Rekeneire}, Nathalie and Duda, {Stephany N.} and Davies, {Mary Ann} and Paula Braitstein",
year = "2016",
month = "6",
day = "9",
doi = "10.1007/s40264-016-0434-9",
language = "English (US)",
pages = "1--18",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Targeted Spontaneous Reporting

T2 - Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale

AU - Rachlis, Beth

AU - Karwa, Rakhi

AU - Chema, Celia

AU - Pastakia, Sonak

AU - Olsson, Sten

AU - Wools-Kaloustian, Kara

AU - Jakait, Beatrice

AU - Maina, Mercy

AU - Yotebieng, Marcel

AU - Kumarasamy, Nagalingeswaran

AU - Freeman, Aimee

AU - de Rekeneire, Nathalie

AU - Duda, Stephany N.

AU - Davies, Mary Ann

AU - Braitstein, Paula

PY - 2016/6/9

Y1 - 2016/6/9

N2 - Introduction: Targeted spontaneous reporting (TSR) is a pharmacovigilance method that can enhance reporting of adverse drug reactions related to antiretroviral therapy (ART). Minimal data exist on the needs or capacity of facilities to conduct TSR. Objectives: Using data from the International epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium, the present study had two objectives: (1) to develop a list of facility characteristics that could constitute key assets in the conduct of TSR; (2) to use this list as a starting point to describe the existing capacity of IeDEA-participating facilities to conduct pharmacovigilance through TSR. Methods: We generated our facility characteristics list using an iterative approach, through a review of relevant World Health Organization (WHO) and Uppsala Monitoring Centre documents focused on pharmacovigilance activities related to HIV and ART and consultation with expert stakeholders. IeDEA facility data were drawn from a 2009/2010 IeDEA site assessment that included reported characteristics of adult and pediatric HIV care programs, including outreach, staffing, laboratory capacity, adverse event monitoring, and non-HIV care. Results: A total of 137 facilities were included: East Africa (43); Asia–Pacific (28); West Africa (21); Southern Africa (19); Central Africa (12); Caribbean, Central, and South America (7); and North America (7). Key facility characteristics were grouped as follows: outcome ascertainment and follow-up; laboratory monitoring; documentation—sources and management of data; and human resources. Facility characteristics ranged by facility and region. The majority of facilities reported that patients were assigned a unique identification number (n = 114; 83.2 %) and most sites recorded adverse drug reactions (n = 101; 73.7 %), while 82 facilities (59.9 %) reported having an electronic database on site. Conclusion: We found minimal information is available about facility characteristics that may contribute to pharmacovigilance activities. Our findings, therefore, are a first step that can potentially assist implementers and facility staff to identify opportunities and leverage their existing capacities to incorporate TSR into their routine clinical programs.

AB - Introduction: Targeted spontaneous reporting (TSR) is a pharmacovigilance method that can enhance reporting of adverse drug reactions related to antiretroviral therapy (ART). Minimal data exist on the needs or capacity of facilities to conduct TSR. Objectives: Using data from the International epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium, the present study had two objectives: (1) to develop a list of facility characteristics that could constitute key assets in the conduct of TSR; (2) to use this list as a starting point to describe the existing capacity of IeDEA-participating facilities to conduct pharmacovigilance through TSR. Methods: We generated our facility characteristics list using an iterative approach, through a review of relevant World Health Organization (WHO) and Uppsala Monitoring Centre documents focused on pharmacovigilance activities related to HIV and ART and consultation with expert stakeholders. IeDEA facility data were drawn from a 2009/2010 IeDEA site assessment that included reported characteristics of adult and pediatric HIV care programs, including outreach, staffing, laboratory capacity, adverse event monitoring, and non-HIV care. Results: A total of 137 facilities were included: East Africa (43); Asia–Pacific (28); West Africa (21); Southern Africa (19); Central Africa (12); Caribbean, Central, and South America (7); and North America (7). Key facility characteristics were grouped as follows: outcome ascertainment and follow-up; laboratory monitoring; documentation—sources and management of data; and human resources. Facility characteristics ranged by facility and region. The majority of facilities reported that patients were assigned a unique identification number (n = 114; 83.2 %) and most sites recorded adverse drug reactions (n = 101; 73.7 %), while 82 facilities (59.9 %) reported having an electronic database on site. Conclusion: We found minimal information is available about facility characteristics that may contribute to pharmacovigilance activities. Our findings, therefore, are a first step that can potentially assist implementers and facility staff to identify opportunities and leverage their existing capacities to incorporate TSR into their routine clinical programs.

UR - http://www.scopus.com/inward/record.url?scp=84973632336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973632336&partnerID=8YFLogxK

U2 - 10.1007/s40264-016-0434-9

DO - 10.1007/s40264-016-0434-9

M3 - Article

C2 - 27282427

AN - SCOPUS:84973632336

SP - 1

EP - 18

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

ER -